Biotechnology Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy – Cartesian Therapeutics (NASDAQ:RNAC) Read more
Biotechnology New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson’s Investigational Drug Meets Primary Goal In Two Studies – Johnson & Johnson (NYSE:JNJ) Read more
